According to one aspect, the disclosure provides a composition for coating a tablet, including an alginate, a natural oil, a modified starch, and a cellulose derivative. According to another aspect, the disclosure provides a method for enteric coating of a tablet, including the step of coating a tablet with a composition including an alginate, a natural oil, a lecithin, and a cellulose derivative. The composition for coating a tablet according to an embodiment of the disclosure is safe as a naturally-derived ingredient and has excellent ability of coating because it can effectively coat even the edge of the tablet. In addition, the composition for coating a tablet according to an embodiment of the disclosure can implement an enteric coating, and thus has excellent heartburn suppression effect.

Described herein are synthetic progestogens, such as 6β,7β:15β,16β-Dimethylene-3-oxo-17α-pregn-4-ene-21,17-carbolactone, as well as pharmaceutical compositions comprising the same. Also described are methods of use.

The invention relates to stable preparations of thymoquinone and methods of making and administering stable preparations of thymoquinone. Embodiments of the methods provide compositions comprising thymoquinone with phosphatidylcholine and/or guggulsterol and/or guggulsterol derivatives and/or sodium cholesteryl sulfate, in tablet, capsule, gel, or ointment forms, and method of administering the preparations.

The present invention relates to pharmaceutical compositions of DPP IV inhibitors with an amino group, their preparation and their use to treat diabetes mellitus.

Disclosed are muscarinic agonist compounds including oxadiazole derivatives, compositions and preparations thereof. Also disclosed are methods of synthesizing such oxadiazole compounds. Further disclosed are methods for treating a subject with said muscarinic agonists or a pharmaceutically suitable form thereof to enhance cognitive function.

This invention relates to pharmaceutical dosage forms for delivery of drugs susceptible to abuse, such as, for example, oxycodone and/or oxymorphone.

Abuse deterrent solid dosage formulations containing 5-({[2-Amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid, and processes for the preparation and administration of these formulations.

The present invention is directed to dosage forms that can be used in therapeutic methods involving the oral co-administration of a combination of at least two drugs, one of which impairs gastrointestinal absorption and one of which does not. The dosage forms are designed so that the drug impairing absorption is not released into the gastrointestinal tract of a patient until after the drugs that do not impair absorption have been released and substantially absorbed. The invention may be used in treatment of migraine using a combination of triptans and NSAIDs or in the treatment of pain using a combination of NSAIDs and opioid analgesics.

The present invention relates to stable solid formulations of vitamin D.sub.3 and to processes for preparation of the same. The present invention provides stabilized compositions comprising vitamin D.sub.3 at least one lipophilic dispersant, one or more antioxidants, at least one adsorbent and one or more pharmaceutically acceptable excipients and further coated with a barrier coating.

Provided is an oral dosage form comprising a deliverable form of iodine for treating symptoms related to fibrocystic breast condition, for prophylactically maintaining breast health, for treating fibrocystic breasts or breast cancer in pre-menopausal women, for prophylactically maintaining prostate health, and for treating benign prostate hyperplasia along with related methods for making and administering such dosage form. More particularly, this disclosure relates to an oral dosage form that is effective to deliver supraphysiologic levels of molecular iodine. The oral dosage form generally comprises a source of iodine and a reactive agent, wherein the source of iodine and/or the reactive agent are provided in excess.